Novira Therapeutics To Present At 2015 AASLD Meeting In San Francisco
DOYLESTOWN, Pa., Oct. 20, 2015 /PRNewswire/ -- Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced that it will present two posters and one oral presentation for its core inhibitors, including its lead candidate, NVR 3-778, at the upcoming 2015 annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.
Late-breaking poster LB-10 on November 16 will describe the safety, pharmacokinetics and HBV DNA reduction efficacy of NVR 3-778 monotherapy in a 28 day Phase 1b clinical study.
Poster 2064 on November 17 will describe the inhibition of HBV RNA encapsidation and secretion by the core inhibitor NVR-3891.
Oral presentation 33 on November 15 at 3:30 PM will describe preclinical antiviral activity of NVR 3-778 against wild-type HBV, HBV nucleos(t)ide resistant variants and representative HBV strains from genotypes A to H.
About NVR 3-778
NVR 3-778 is a small molecule, direct acting antiviral, for oral administration in patients with Chronic Hepatitis B (CHB) that inhibits the HBV core or capsid protein. HBV core is a novel and promising drug target with multiple activities required for viral replication and persistence. Inhibition of the HBV core protein function by NVR 3-778 offers the potential for more efficient suppression of virus production and replication, leading to improved durable viral suppression and functional cure rates. NVR 3-778 completed a Phase 1a clinical trial in 2014 and is currently enrolling a Phase 1b clinical trial.
Hepatitis B infection presents a significant unmet medical need with an estimated 350 million people worldwide living with chronic HBV infection. A significant number of patients with chronic infection incur a higher risk of developing cirrhosis and cancer. It is estimated that 60% of hepatocellular carcinoma (liver cancer) is a direct consequence of HBV infection. Current drugs approved for the management of CHB include PEG-Interferon and nucleot(s)ides which can effectively suppress virus replication, but rarely lead to a cure.
About Novira Therapeutics
Novira Therapeutics, Inc., is a privately held biopharmaceutical company focused on discovery and development of first-in-class antiviral drugs for the treatment of chronic HBV infection (CHB), a global disease with a high level of unmet medical need. The company is employing innovative chemistry and biology technologies to discover small molecule inhibitors of the HBV core or capsid protein as well as other drugs with novel mode of action. The company's novel antivirals will offer the potential to address the limitations of current CHB therapies when used either as mono-therapy or in combination with existing standards of care.
For more information, visit www.noviratherapeutics.com.
Christian S. Schade
Chief Executive Officer
Matt Middleman, M.D.
T: (212) 845-4271
T: (212) 845-4272
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/novira-therapeutics-to-present-at-2015-aasld-meeting-in-san-francisco-300162508.html
SOURCE Novira Therapeutics, Inc.